WARREN, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, announced today that Fabian Tenenbaum, Chief Executive Officer, will present at two investor conferences in September: H.C. Wainwright 22nd Annual Global Investment Conference and Cantor Fitzgerald Virtual Global Healthcare Conference.
H.C. Wainwright 22nd Annual Global Investment Conference
||Monday, September 14, 2020
||5:00 PM ET
Cantor Fitzgerald Virtual Global Healthcare Conference
||Thursday, September 17, 2020
||2:40 PM ET
A live audio webcast and replay of the presentations will be available in the Investors section on the Company’s website at www.bellerophon.com.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.
Source: Bellerophon Therapeutics, Inc.